Revolutionizing Early Detection of Oral Cancer

Transforming detection, improving lives

Learn More

Patented Technology

Innovative methodology. Proven accuracy.*

Learn More

BeVigilant OraFusion System

The first and only point-of-care test to aid clinicians in the early detection of oral cancer

Learn More

Peace of Mind
Sense of Urgency

Increasing accuracy in early oral cancer detection

Learn More

Granted FDA Breakthrough Device Designation

The BeVigilant™ OraFusion™ System** is Not Available For Sale in the U.S.

Oral Cancer Risk is Escalating

Head and neck cancer, including oral cancer, is the sixth most common cancer in humans worldwide. More than 90% of oral cancers are squamous cell carcinomas. Current 5-year survival rates are less than 50% with over 70% diagnosed at stage III or stage IV. Find out what that means for you as a provider, and for your patients.

Learn More

Innovative Technology

Vigilant Biosciences® develops advanced and accurate methods to aid in the early detection of oral cancer by identifying several unique biomarkers shown to be associated with oral cancer. Discover how this life-saving technology can make a difference for your patients.

Learn More

Why BeVigilant?

The BeVigilant™ OraFusion™ System is based on patented technology that detects specific biomarkers clinically shown to be associated with early-stage cancers. Our technology aims to elevate survival outcomes in oral cancer through early detection.

Learn More

Vigilant Biosciences® vision is to transform the future of healthcare by becoming the global leader in early cancer detection, ultimately creating a world where cancer is identified at its most treatable stages, thereby saving lives and transforming patient outcomes.